AstraZeneca CEO links Europe ’s Covid surge to rejection of its vaccine

Scientists sceptical about Pascal Soriot ’s suggestion Oxford jab may give longer-lasting protectionCoronavirus – latest updatesSee all our coronavirus coverageScientists have reacted with scepticism to claims by AstraZeneca ’s CEO that low uptake of the Oxford/AstraZeneca jab among elderly Europeans could explain thecurrent surge in Covid-19 infections in mainland Europe.Pascal Soriot told BBC Radio 4 ’s Today programme that differences in T-cell immunity between the vaccines might mean that those who received the Oxford/AstraZeneca jab had longer-lasting immune protection against the virus. T- cells are a class of immune cells that educate antibody-producing B cells about the nature of the vir al threat and directly kill infected cells.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus Vaccines and immunisation AstraZeneca Society Science Health UK news World news Pharmaceuticals industry Source Type: news